5. Unless paragraphs 6 to 10 apply, the fee payable under regulation 33(3) in connection with the holding of a marketing authorization relating to a medicinal product of a kind described in column 1 of the following table is the applicable fee specified in the corresponding entry in column 2 of that table.
Column 1 Kind of product | Column 2 Fee payable | |||
|---|---|---|---|---|
| 1. New Active Substance | £23,025 | |||
| 2. Other kinds of Medicinal Product— | ||||
| (a) | Any product (not being a derivative of a new active substance) in respect of which a marketing authorization has been granted in consequence of a complex application submitted on or after 1st April 1989 | £9,481 | ||
| (b) | Prescription Only Medicine | |||
| (i) | Standard Fee | £2,371 | ||
| (ii) | Reduced Rate Fee | £1,183 | ||
| (iii) | Maintenance Fee | £384 | ||
| (c) | Pharmacy Medicine | |||
| (i) | Standard Fee | £1,038 | ||
| (ii) | Reduced Rate Fee | £519 | ||
| (iii) | Maintenance Fee | £192 | ||
| (d) | General Sale List Medicine | |||
| (i) | Standard Fee | £429 | ||
| (ii) | Reduced Rate Fee | £213 | ||
| (iii) | Maintenance Fee | £93 | ||
| (e) | Herbal Remedy | £113 | ||
| (f) | National homoeopathic product | £81 | ||
| (g) | Homoeopathic or anthroposophic product which is the subject of a licence of right | £74 | ||
6. In the case of an article or substance to which Part II of the Act applies by virtue of the Medicines (Surgical Materials) Order 1971(1), the fee payable under regulation 33(3) in connection with the holding of a marketing authorization or licence is—
(a)£527, in the case of a standard fee;
(b)£260, in the case of a reduced rate fee; or
(c)£110, in the case of a maintenance fee.
7. Unless paragraph 8 applies, where a marketing authorization is held in respect of a derivative of a new active substance, the fee payable under regulation 33(3) is—
(a)£9,481, where the medicinal product to which the authorization relates has a different route of administration from that of the new active substance; or
(b)£6,400, in any other case.
8.—(1) The fee specified in—
(a)paragraph 5 for a new active substance; and
(b)in paragraph 7 for a derivative of a new active substance,
is only payable for the five relevant fee periods following that in which the marketing authorization is granted.
(2) The fee payable in accordance with entry 2(a) of the table set out in paragraph 5 is only payable for the three relevant fee periods following the year beginning 1st April during which the marketing authorization is granted.
(3) Where a marketing authorization is surrendered and at the same time another marketing authorization held by the authorization holder is varied so as to include in that other authorization the provisions of the first authorization, the fee payable—
(a)for the five relevant fee periods following the fee period during which the marketing authorization is granted is the fee specified at entry 1 of the table set out in paragraph 5, where the first authorization relates to a new active substance;
(b)in all other cases, for each fee period mentioned in sub-paragraph (2), is the fee specified at entry 2(a) of that table.
(4) In respect of fee periods following those referred to in sub-paragraphs (1) to (3) of this paragraph, the periodic fees are the appropriate fees for the kind of medicinal product in question specified in entries 2(b), (c) or (d) of the table set out in paragraph 5.
(5) In connection with the holding of a marketing authorization in respect of a limited use drug or a derivative of a limited use drug—
(a)where turnover exceeds £200,000, until the expiry of the five relevant fee periods following the fee period during which the marketing authorization was granted, the periodic fee payable is the fee that would be payable if the drug were, respectively, a new active substance or a derivative of a new active substance;
(b)where turnover does not exceed £200,000 or where a periodic fee has been payable in respect of the limited use drug or derivative of a limited use drug for five relevant fee periods following the fee period during which the marketing authorization was granted, the periodic fee payable is the fee payable in respect of a prescription only medicine in accordance with entry 2(b)(i) of the table set out in paragraph 5.
9. Where a marketing authorization relates to any two or more medicinal products of a kind described in entries 2(b), (c) or (d) of column 1 of the table in paragraph 5, the fee payable under regulation 33(3) shall be the lower of the fee specified as corresponding to those entries in column 2 of that table.
10. Where a reduced rate fee or a maintenance fee may be payable in respect of any relevant fee period and an authorization holder does not submit evidence of turnover in relation to the relevant calendar year to the satisfaction of the licensing authority, the periodic fee payable shall, where applicable, be the standard fee for each description of medicinal product in respect of which a marketing authorization is held by the authorization holder.
11.—(1) Unless sub-paragraph (3) applies, the fee payable under regulation 33(3) in connection with the holding of a manufacturer’s licence is £457.
(2) The fee payable under regulation 33(3) in connection with the holding of a manufacturing authorisation is £457.
(3) The fee payable under regulation 33(3) in connection with the holding of a manufacturer’s licence which relates to the import of exempt imported products from a third country is the fee payable in accordance with sub-paragraph (1) and an additional amount calculated in accordance with paragraph 15.
12.—(1) Subject to sub-paragraph (2) and to paragraphs 13 and 16, the fee payable under regulation 33(3) in connection with the holding of a wholesale dealer’s licence is £281.
(2) The fee payable under regulation 33(3) is £168 where the wholesale dealer’s licence—
(a)relates to anything done in a registered pharmacy by or under the supervision of a pharmacist and amounts to wholesale dealing, where such dealing constitutes no more than 15% of the total turnover of the sale of authorised medicinal products carried on at that pharmacy;
(b)does not relate to anything done in a registered pharmacy, where the total turnover of the sale by way of wholesale dealing in authorised medicinal products does not exceed £35,000; or
(c)relates to general sale list medicines only.
(3) For the purposes of sub-paragraph (2), the total turnover shall be calculated in accordance with Part 2 of this Schedule and the references to “marketing authorization” and “authorization holder” in Part 2 shall be construed as if they were references to “wholesale dealer’s licence” and “licence holder”, respectively.
13. Where in respect of any relevant fee period, the holder of a wholesale dealer’s licence does not submit evidence of turnover in relation to the relevant calendar year to the satisfaction of the licensing authority, the periodic fee payable shall be the fee prescribed in paragraph 12(1).
14. The fee payable under regulation 33(3) in connection with the holding of a wholesale dealer’s licence which relates to exempt imported products is the fee payable in accordance with paragraphs 12 and 13 and an additional amount calculated in accordance with paragraph 15.
15.—(1) The additional amount referred to in paragraph 11(3) and 14 in relation to any fee period shall be the fee specified in the entry in column 2 of the following table corresponding to the estimated number of special import notices for that fee period specified in column 1.
Column 1 Number of special import notices | Column 2 Additional amount |
|---|---|
| 1 to 20 | £126 |
| 21 to 100 | £505 |
| 101 to 1,000 | £2,020 |
| 1,001 to 5,000 | £10,100 |
| 5,001 to 20,000 | £25,250 |
| 20,001 to 50,000 | £50,500 |
| 50,001 to 100,000 | £101,000 |
| 100,001 or more | £151,500 |
(2) For the purposes of this paragraph, the estimated number of special import notices for any fee period shall be the number notified in writing to the licence holder by the licensing authority before the start of that fee period as the number of such notices which the authority estimate will be given by the holder during the fee period.
16. The fee payable under regulation 34(2) in connection with the holding of a clinical trial authorisation is £342.
17. The fee payable under regulation 33(3) in connection with the holding of a traditional herbal registration is £96.
S.I. 1971/1267; Part II of the Act is applied by Article 3 of the Order which has been amended by S.I. 1994/3119, 2004/1031 and 2006/2407.